Barrington analyst Michael Petusky raised the firm’s price target on U.S. Physical Therapy to $122 from $120 and keeps an Outperform rating on the shares. The company reported strong Q4 results and offered solid fiscal 2024 guidance, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on USPH:
- U.S. Physical Therapy sees FY24 adjusted EBITDA $80M-$85M
- U.S. Physical Therapy reports Q4 operating EPS 59c, consensus 57c
- USPH Upcoming Earnings Report: What to Expect?
- U.S. Physical Therapy assumed with a Market Perform at William Blair
- U.S. Physical Therapy price target raised to $120 from $111 at Barrington
